Portal Bio

Problem: Effective and scalable cell engineering is a fundamental challenge that has limited the development of next generation therapeutics. Our technology dramatically simplifies the process of delivering materials into cells and could underpin a whole new generation of life changing cell therapies broadly available at the point-of-care . Solution: Portal leverages precision deformation of cells to temporarily disrupt their membrane and enable robust delivery of materials. Discovered by our founder at MIT, the tech is now the basis of 50 partnerships with biopharma and academia. This simple approach can integrate into many workflows to create next gen cell therapies. Target Markets: Hospitals, Biotech, Pharma, Academia Looking for business opportunities in: Funding, Market Access, Investor, Corporation Technology Readiness Level: TRL 6-7 Minimum Viable Product Contact info: Armon Sharei armon@portal.bio